Search
Nitrazepam
go.drugbank.com/drugs/DB01595ApprovedA benzodiazepine derivative used as an anticonvulsant and hypnotic.
Synonyms: N-desmethylnimetazepamProducts: EATAN NNN-8828
go.drugbank.com/drugs/DB18361InvestigationalNN-8828 is an anti-interleukin 21 monoclonal antibody.
Gadobenic acid
go.drugbank.com/drugs/DB00743ApprovedInvestigational[A263086] It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. … Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver.
Categories: Compounds used in a research, industrial, or household settingPyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
International brands: Kalymin NBrilliant blue G
go.drugbank.com/drugs/DB15594ApprovedBrilliant Blue G is used in an ophthalmic solution for staining the internal limiting membrane (ILM) of the eye during ophthalmic procedures. … Brilliant blue G, like its name, imparts a vibrant blue color, facilitating identification of the ILM. It was approved by the FDA for ophthalmic use on December 20, 2019.[L10830]
Categories: Compounds used in a research, industrial, or household settingNOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.
Veglin
go.drugbank.com/drugs/DB05890ExperimentalVEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma
Miltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalMiltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease.
Tedizolid
go.drugbank.com/drugs/DB14569ApprovedInvestigationalThis product is currently available as both an oral tablet and as a powder for intravenous injection.[L11232] … Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesTralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalWhile AD is a heterogenous condition with a variety of apparent genetic and environmental causes,[A242422] it is primarily driven by the pro-inflammatory cytokine interleukin-13 (IL-13). … [A242427] Tralokinumab is a fully human IgG4 monoclonal antibody targeted against IL-13.